Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page’s revision marker was updated from v3.6.3 to v3.6.4, signaling a new version of the page template; no study information or functionality appears affected.
    Difference
    0.1%
    Check dated 2026-07-27T05:58:37.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The page’s revision tag was updated from v3.6.2 to v3.6.3, replacing the previous revision. This reflects a small update to the page’s revision history without altering displayed study details.
    Difference
    0.1%
    Check dated 2026-07-05T13:43:21.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The page shows a new revision tag, v3.6.2, replacing the previous v3.6.0. This update appears to be a maintenance/versioning change rather than an alteration to study information or user-visible content.
    Difference
    0.1%
    Check dated 2026-06-28T08:22:13.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page adds new navigation sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', and standardizes the Intervention/Treatment heading. It also introduces metadata labels 'Last verified' and 'Last known status was:' plus a 'Revision: v3.6.0' indicator to reflect updated documentation structure.
    Difference
    2%
    Check dated 2026-06-14T05:05:08.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.5.4 to v3.5.5, indicating a minor behind-the-scenes update to the study record. This does not alter the study details or eligibility criteria.
    Difference
    0.1%
    Check dated 2026-06-07T01:42:04.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    Virogen Biotechnology Inc. was added as sponsor and Angimmune LLC was removed as a collaborator. The study record revision was updated from v3.5.3 to v3.5.4.
    Difference
    0.3%
    Check dated 2026-05-16T10:27:01.000Z thumbnail image

Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.